A retrospective study of capecitabine/temozolomide (captem) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy

Journal of the Pancreas

Volumn 14, Issue 5, 2013, Pages 498-501

  Saif, Muhammad Wasif ^a   Kaley, Kristin ^b   Brennan, Marianne ^b   Garcon, Marie Carmel ^c   Rodriguez, Gladys ^c   Rodriguez, Teresa ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

Author keywords

Capecitabine; Neuroendocrine tumors; Pancreatic cancer; Temozolomide

Indexed keywords

CAPECITABINE; OCTREOTIDE; TEMOZOLOMIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; METASTATIC PANCREATIC NEUROENDOCRINE TUMOR; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; NEUTROPENIA; PANCREATIC NEOPLASMS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883791816     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dimou AT, Syrigos KN and Saif MW. Neuroendocrine tumors of the pancreas: what's new. Highlights from the 2010 ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 22-24, 2010. JOP. J Pancreas (Online) 2010; 11:135-138. [PMID 20208321]
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063-3072. [PMID 18565894]
3. Stevenson R, Libutti SK, Saif MW. Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP. J Pancreas (Online) 2013; 14:152-154. [PMID 23474560]
4. Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: entering a new era. JOP. J Pancreas (Online) 2012; 13:169-173. [PMID 22406593]
5. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86:944-948. [PMID 10491519]
6. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401-406. [PMID 16421420]
7. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24(18S): Abstract 4044.
8. Murakami J, Lee YJ, Kokeguchi S, Tsujigiwa H, Asaumi J, Nagatsuka H, et al. Depletion of O6-methylguanine -DNA methyltransferase by O6-benzylguanine enhances 5 -FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep 2007; 17:1461-1467. [PMID 17487405]
9. Isacoff WH, Moss RA, Pecora AL, Fine RL. Temozolomide/ capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol 2006; 24(18S): Abstract 14023.
10. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117:268-275. [PMID 20824724]
11. Julka PK, Doval DC, Gupta S, Rath GK. Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines. Br J Radiol 2008; 81:444-449. [PMID 18316345]
12. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute at the National Institute of Health: Bethesda, MD, USA.
13. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-6463. [PMID 19704057]
14. Oberstein PE and Saif MW. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 2012; 6:41-51. [PMID 22253554]
15. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514-523. [PMID 21306238]
16. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513. [PMID 21306237]